How to Test for Staph Infection: Cultures, Swabs & More

Testing for a staph infection starts with collecting a sample from the suspected site, whether that is a wound, the inside of your nose, or your blood, and sending it to a microbiology lab for culture and identification. The specific tests used depend on where the infection is, how severe it is, and whether your doctor suspects a drug-resistant strain like MRSA. The process can be as simple as a cotton swab pressed into an open wound or as involved as drawing multiple sets of blood cultures from different veins. What follows in the lab ranges from overnight growth on agar plates to same-day molecular assays that can identify staph and its resistance genes in under two hours.

How Wound Swabs Are Collected and Why Technique Matters

If you have a skin wound that looks infected, the most common first step is a wound swab. A clinician takes a sterile swab and rolls it across the wound bed, then sends it to the lab in a transport tube. But how the swab is used turns out to be surprisingly important. There are two main swabbing approaches. In the Levine technique, the swab is pressed into a small area of the wound and rotated with enough pressure to squeeze fluid up from the tissue underneath. In the Z technique, the swab is drawn in a zigzag pattern across the wound surface without pressing down. A study comparing the two found that the Levine technique detected significantly more organisms in both acute and chronic wounds, likely because the pressure expresses bacteria from just below the wound surface rather than only picking up whatever is sitting on top.¹

The swab material itself also affects results. A study comparing different nasal swab types for MRSA screening found that nylon flocked swabs and cellular foam swabs recovered significantly more bacteria than conventional rayon swabs. Some rayon swabs recovered essentially zero organisms under certain conditions. The best-performing combination was a flocked swab paired with Amies preservation medium.² If you are being swabbed at a clinic that still uses older-style rayon swabs, the test is more likely to miss organisms that are actually present.

Nasal Swabs for MRSA Screening

The anterior nares, the front part of each nostril, are a favorite hiding spot for Staphylococcus aureus. Roughly a third of healthy people carry staph in their noses without any symptoms, and a smaller fraction carry MRSA specifically. Hospitals screen for nasal MRSA carriage in certain situations, such as before surgery or on admission to an intensive care unit, to guide infection-prevention measures. The swab is simple: a clinician rotates a swab inside each nostril for a few seconds, and it goes to the lab for either culture or a rapid molecular test.

Nasal screening is useful but imperfect. One study of hospital patients found that nasal MRSA swabs had a sensitivity of about 58% compared with full bacterial culture, meaning the swab missed roughly four out of ten true carriers. However, its negative predictive value was high, around 98%, so a negative result was a strong signal that you were not carrying MRSA.³ In other words, these swabs are better at ruling out MRSA than ruling it in.

What the Lab Does With Your Sample

Once a swab or fluid sample arrives at the microbiology lab, the standard approach is to streak it onto culture plates and incubate it overnight. One traditional medium is mannitol salt agar, a plate that favors staphylococci because of its high salt concentration. S. aureus colonies typically ferment mannitol and turn the plate yellow. But this step is less definitive than it sounds. A study collecting strains from clinical labs in Nigeria found that all 171 strains of coagulase-negative staphylococci, species that are usually less dangerous, also grew on mannitol salt agar and fermented mannitol, making them visually indistinguishable from S. aureus on the plate.⁴ Growth on culture plates is the starting point, not the final answer.

To confirm that the colonies are actually S. aureus, labs use additional tests. The coagulase test checks whether the organism produces an enzyme that clots blood plasma, a hallmark of S. aureus. There are tube and slide versions of the test. Latex agglutination kits offer a faster alternative: tiny latex beads coated with antibodies clump together in the presence of specific S. aureus surface proteins. One early evaluation of a commercial latex test found it correctly identified 159 of 160 S. aureus isolates and correctly ruled out 266 of 267 non-aureus strains.⁵ These rapid bench tests give the lab a confident identification within minutes rather than waiting for another round of overnight growth.

MALDI-TOF Mass Spectrometry

Many hospital labs now use a technology called MALDI-TOF mass spectrometry, which identifies bacteria by analyzing the unique protein fingerprint of a colony. A technician smears a tiny amount of bacterial growth onto a metal target, adds a chemical matrix, and fires a laser at it. The resulting spectrum is compared against a database to identify the species. The method is fast, often giving a result in minutes from a viable colony, and highly accurate. One review noted that MALDI-TOF was shown to identify staphylococci species with about 99% accuracy, rivaling gene-sequencing methods that take much longer.⁶

Database quality matters, though. When one group tested a commercial MALDI-TOF database against non-aureus staphylococci, only 67% of isolates met the threshold for reliable species-level identification. After expanding the database with additional reference spectra, the identification rate jumped to 97%.⁴ For S. aureus itself, identification is seldom a problem. The gaps tend to show up with rarer species that the default database has fewer reference entries for.

Testing for Antibiotic Resistance

Identifying the organism is only half the job. The lab also needs to figure out which antibiotics will work against it. For staph infections, the most urgent question is usually whether the strain is methicillin-resistant, because MRSA requires a different treatment strategy than ordinary staph.

The workhorse method for detecting MRSA in the lab is the cefoxitin disk diffusion test. A paper disk soaked in cefoxitin (a cephalosporin antibiotic) is placed on an agar plate spread with the staph isolate. After incubation, the lab measures the zone of inhibited growth around the disk. A small zone means the bacteria grew right up to the disk and are resistant. Multiple studies have confirmed that the cefoxitin disk diffusion test accurately predicts the presence of the mecA gene, the genetic basis of methicillin resistance in S. aureus, and performs better than older oxacillin-based disk tests.⁷⁸ One caveat: cefoxitin disk testing was developed for S. aureus, and it does not work well for every staphylococcal species. For S. schleiferi, for example, oxacillin testing with species-specific breakpoints performed much better, while cefoxitin missed the majority of mecA-positive strains.⁹

The D-Zone Test for Clindamycin Resistance

Clindamycin is a common antibiotic choice for staph skin infections, especially in people with penicillin allergies. But some staph strains carry a hidden form of resistance: they test susceptible to clindamycin on standard panels yet can switch on resistance when exposed to erythromycin. This is called inducible clindamycin resistance, and missing it can lead to treatment failure.

To catch it, labs perform the D-zone test. An erythromycin disk and a clindamycin disk are placed close together on a plate inoculated with the staph isolate. After overnight incubation, the lab looks at the shape of the zone of inhibition around the clindamycin disk. If the zone is flattened on the side facing the erythromycin disk, forming a D shape, the strain has inducible resistance and clindamycin should not be used.¹⁰ The distance between the two disks matters: one study found that moving the disks from 25 mm apart to 15 mm apart increased the number of positive D-zone results among S. aureus isolates by over 84%.¹¹ Labs that use a wider spacing risk missing resistant strains.

Rapid Molecular Tests

Traditional culture-based identification can take one to three days, depending on the organism and the test pipeline. When speed matters, such as in bloodstream infections or before emergency surgery, labs increasingly turn to PCR-based assays that detect staph DNA directly.

For nasal MRSA screening, PCR targeting the mecA gene alongside S. aureus-specific gene markers can deliver a result from a swab after a brief enrichment period in broth, without waiting for colonies to grow on a plate.¹² Newer-generation commercial panels go further. One assay targeting both the mecA and mecC genes correctly categorized over 98% of MRSA strains and all methicillin-susceptible strains tested.¹³

In bloodstream infections, PCR panels can be run directly on a positive blood culture bottle. One study found that using a rapid blood culture identification PCR panel for patients with methicillin-susceptible S. aureus bacteremia cut the time to optimal antibiotic therapy by roughly 20 hours and shortened the duration of bacteremia itself.¹⁴ That time savings translates into real clinical benefit, because every hour on the wrong antibiotic for a bloodstream staph infection increases the risk of complications.

The trade-off is cost. A cost-effectiveness analysis at one academic medical center found the per-positive-carrier cost of PCR screening was roughly $603 compared with $364 for traditional culture. But the PCR-screened group saw a reduction of about 2.9 hospital-acquired MRSA infections per month, translating to estimated savings of over $142,000 per month in hospitalization costs.¹⁵ The upfront expense of the test is higher, but the downstream costs of missed or delayed detection can dwarf it, particularly in intensive care settings.¹⁶

Blood Cultures for Serious Staph Infections

When staph gets into the bloodstream, blood cultures are the gold standard for diagnosis. A nurse draws blood from a vein, usually two separate sets from different sites, and injects it into aerobic and anaerobic culture bottles. The bottles go into an automated incubation system that monitors for signs of bacterial growth, typically flagging a positive within 12 to 24 hours for fast-growing organisms like S. aureus.

Drawing multiple sets is not just a formality. Staphylococci live on the skin, and a single positive blood culture can represent contamination during the blood draw rather than a true infection. This is especially tricky with coagulase-negative species that are common skin commensals. Even Staphylococcus lugdunensis, a species known for causing aggressive infections, was found to be a contaminant in over 81% of single-positive blood culture cases in a large retrospective study. In that study, significant bacteremia was far more common when multiple sets were positive and when the patient had an intravascular device like a central line.¹⁷

For confirmed S. aureus bacteremia, doctors typically draw repeat blood cultures every day or two until the results come back negative, to confirm the infection is clearing. Research has highlighted a phenomenon called “skip positivity,” where a single negative blood culture is followed by another positive one. This means a single negative set is not always enough to confirm clearance, and serial negative cultures provide stronger evidence that antibiotic treatment is working.¹⁸

When Surface Swabs Are Not Enough

Swabbing a wound surface is convenient, but it has real limitations. The bacteria on the wound surface are not always the same ones causing the deeper infection. A prospective study of spinal-cord-injured patients with advanced pressure ulcers compared surface swab cultures with deep-tissue biopsies taken during surgery. The two methods agreed on the causative organism in only about 22% of cases. The surface swab yielded the wrong organism in roughly a third of cases, gave a false negative about a quarter of the time, and was falsely positive about 16% of the time.¹⁹ For deep or chronic wounds, a tissue biopsy or aspirated fluid gives the surgeon a much more accurate picture of what is actually driving the infection.

Implant-associated infections present an even harder diagnostic challenge. Staph species, particularly S. epidermidis, form biofilms on prosthetic joints and orthopedic hardware, essentially encasing themselves in a protective slime layer that standard swabs cannot reach effectively. In an animal model of chronic implant infection, researchers found abundant staph growth embedded in the bone graft, but sonication of the metal implant plates, a process that uses ultrasound vibrations to shake bacteria off surfaces, dislodged only a small fraction of the organisms. All 18 implant plates from infected animals were positive by molecular testing after sonication, but the bacterial counts recovered were far lower than what the tissue itself harbored.²⁰ Diagnosing biofilm infections often requires removing the implant and combining sonication with culture and PCR to catch the organism.

Pre-Surgical Screening and What Comes After a Positive Result

Many hospitals now screen patients for nasal staph carriage before major surgery, particularly before cardiac, orthopedic, and vascular procedures. The logic is straightforward: if you are carrying S. aureus in your nose, it can migrate to the surgical site and cause a post-operative infection. Identifying carriers ahead of time allows for a brief decolonization protocol, typically involving mupirocin nasal ointment and chlorhexidine body washes in the days before surgery.

A health technology assessment found that this targeted approach, screening first and then decolonizing carriers, reduced S. aureus surgical site infections by about 68% compared with placebo in patients undergoing cardiothoracic, vascular, orthopedic, or general surgery.²¹ The same review noted that decolonizing patients who were not staph carriers had little to no effect, which argues against a universal “treat everyone” approach. There are also practical concerns about universal decolonization without screening: it may accelerate the development of mupirocin resistance, and it prevents clinicians from adjusting surgical antibiotic prophylaxis for patients who specifically carry MRSA.²²

Toxin and Virulence Gene Testing

Not all staph strains are equally dangerous, and in certain clinical situations labs look for specific toxin genes to guide treatment. One of the most studied is the Panton-Valentine leukocidin gene, which produces a toxin that destroys white blood cells and is linked to severe skin abscesses and necrotizing pneumonia. PVL-positive strains are more common in community-acquired MRSA than in hospital strains. In one French survey, the community-associated MRSA clone ST80 was PVL-positive and disproportionately found in younger patients with deep skin infections.²³

PVL testing is done by PCR and is not part of routine staph workups. It tends to be ordered when a patient presents with recurrent abscesses, severe soft-tissue infections, or necrotizing pneumonia, particularly in otherwise healthy young people. A real-time PCR assay for the PVL gene found low prevalence among general S. aureus bloodstream and respiratory isolates but much higher rates among MRSA skin isolates, with 15 out of 25 testing positive in one series.²⁴ Knowing whether a strain carries PVL can influence decisions about antibiotic choice, whether to drain an abscess surgically, and how aggressively to monitor for complications.